NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Pacira BioSciences, Inc. (PCRX) Stock Analysis

Pacira BioSciences, Inc. (PCRX) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

PCRX

$26.35

−$0.25 (−0.94%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PCRX with… →

PCRX Key Statistics

As of Sep 4, 2026
Trading
Open
$26.38
Previous Close
$26.60
Day's Range
26.31–26.65
52-Week Range
18.80–27.66
Volume
481.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.27
Valuation
Market Cap
$1.05B
P/E Ratio
75.29
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
7.64
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
11.21
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.41
EPS (ttm)Profit attributable to each share over the last twelve months.
0.35
Financials (FY)
Revenue (FY)
$726.41M+3.63%
Net Income (FY)
$7.03M
Profit marginThe share of revenue left as profit after all costs and taxes.
1.96%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
39.86M
1-Year Return
−1.42%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
563.94K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PCRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.82%
2025+37.37%
2024−44.16%
2023−12.61%
2022−35.83%
2021+0.55%
2020+32.10%
2019+5.30%
2018−5.76%
2017+41.33%
2016 (partial year)−25.08%

As of September 4, 2026.

PCRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$726.41M$7.03M1.0%
2024$700.97M−$99.56M−14.2%
2023$674.98M$41.96M6.2%
2022$666.82M$15.91M2.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$726.41M$576.66M$19.19M$7.03M1.0%
2024$700.97M$530.54M$89.87M−$99.56M−14.2%
2023$674.98M$490.31M$87.68M$41.96M6.2%
2022$666.82M$467.53M$60.02M$15.91M2.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PCRX Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricPCRXDrug Manufacturers - Specialty & Generic medianvs median
P/E75.2919.273.9x the median
P/S ratio1.412.3039% below
Profit margin1.96%−3.14%5.1 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pacira BioSciences, Inc. (PCRX) is capitalised at $1.05B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 825 employees.

The 52-week range on file runs from $18.80 to $27.66. PCRX last closed at $26.35 on September 4, 2026. That is −$0.25 (−0.94%) against the previous close. The latest close sits 40.16% above that 52-week low.

Financial Health

In fiscal 2025, Pacira BioSciences, Inc. reported revenue of $726.41M. That is +3.63% against the prior fiscal year, when revenue was $700.97M. Net income for the same year was $7.03M. Profit margin runs at 1.96%. That is 5.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 0.35.

Across the 4 fiscal years on file, revenue moves from $666.82M in 2022 to $726.41M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

PCRX trades at a trailing price-to-earnings ratio of 75.29. That is 3.9 times the Drug Manufacturers - Specialty & Generic median of 19.27. The forward P/E on file is 7.64. The PEG ratio, which sets the P/E against expected earnings growth, reads 11.21. The price-to-sales ratio is 1.41. On price-to-sales that is 38.7% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year price return is −1.42%. Measured over 10 years, that is −3.85% a year compounded. Beta against the wider market is reported at 0.27. Daily returns over the trailing 10 years annualize to a volatility of 46.09%.

Growth & Income

The record shows no dividend for PCRX.

So far in 2026 the price is +1.82%. The strongest complete calendar year on file is 2017 at +41.33%; the weakest is 2024 at −44.16%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Pacira BioSciences, Inc. (PCRX) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pacira BioSciences, Inc. PCRX $1.05B 75.3
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Pacira BioSciences, Inc. trades at a P/E of 75.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Visit website →